Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Antibody Treatment Slows Lung Cancer Growth in Mouse Model

By BiotechDaily International staff writers
Posted on 17 Mar 2014
Image: Space-filling model of the peptide hormone vasopressin (Photo courtesy of Wikimedia Commons).
Image: Space-filling model of the peptide hormone vasopressin (Photo courtesy of Wikimedia Commons).
A monoclonal antibody that specifically binds to the surface marker ProAVP (pro-vasopressin) impaired the growth of small-cell lung cancer tumors in a mouse model.

Investigators at Dartmouth College (Hanover, NH, USA) previously had demonstrated that human small-cell lung cancer (SCLC) seemed to universally express the vasopressin gene, and this led to the presence of a cell surface marker representing the entire pro-hormone precursor.

Vasopressin, which is derived from a pro-hormone precursor that is synthesized in the hypothalamus and stored in vesicles at the posterior pituitary, is a peptide hormone that controls the reabsorption of molecules in the tubules of the kidneys by affecting the tissue's permeability. It also increases peripheral vascular resistance, which in turn increases arterial blood pressure. It plays a key role in homeostasis, by the regulation of water, glucose, and salts in the blood.

The investigators treated a group of SCLC mice with MAG-1, a mouse monoclonal antibody specific for the pro-vasopressin C-terminal moiety. They reported in the February 14, 2014, online edition of the journal Frontiers in Oncology that the antibody attached to SCLC cells and it was internalized. Antibody treatment decreased the rate of increase in tumor size by half, and doubling time by about three-fold. Normal tissues seemed not to be affected.

"We are developing methods of antibody-targeted treatment for recurrent small-cell lung cancer," said senior author Dr. William G. North, professor of physiology at Dartmouth College. "Targeting with a humanized MAG-1 can likely be effective, especially when given in combination with chemotherapy, for treating a deadly disease for which there is no effective therapy."

Related Links:

Dartmouth College



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.